Head and Neck Cancer - Featured Clinical Trials
The following list shows Featured Clinical Trials for a specific type of cancer. You may also want to view:
Combination Therapy for Head and Neck Cancer
(Posted: 03/23/2004, Updated: 10/14/2010) - No standard therapy currently exists for head and neck cancer that recurs after treatment with radiation. Laboratory studies have shown that bortezomib (Velcade), a new type of cancer drug called a proteasome inhibitor, inhibits growth of head and neck cancer cells. This clinical study is the first test of whether bortezomib can increase the effectiveness of repeat radiation treatment for patients whose head and neck cancer has recurred.
Pioglitazone for Oral Premalignant Lesions
(Posted: 04/20/2010) - In this trial, patients with oral leukoplakia will be randomly assigned to receive either pioglitazone or placebo pills daily for 6 months.
Preventing Mucositis in Head and Neck Cancer Patients
(Posted: 03/20/2007, Updated: 06/17/2008) - In this trial, patients undergoing combination chemotherapy and radiation therapy (chemoradiotherapy) for advanced head and neck cancer will receive intravenous palifermin or placebo before and during cancer treatment to prevent mucositis, a common but serious side effect of chemoradiotherapy for this type of cancer.
Chemoprevention Trial for Head and Neck Cancer
(Posted: 02/01/2005, Updated: 03/05/2008) - In this study, researchers are investigating the ability of pioglitazone, a drug used to treat type II diabetes, to reverse leukoplakia and prevent it from developing into head and neck cancer.
Treatment for Recurrent Head and Neck Cancer
(Posted: 01/31/2006, Updated: 01/08/2007) - In this clinical trial, researchers seek to determine if giving concurrent radiation therapy and chemotherapy to patients with inoperable, recurrent head and neck cancer who were treated initially with radiation therapy will improve survival rates for these patients.
(Posted: 03/23/2004, Updated: 10/14/2010) - No standard therapy currently exists for head and neck cancer that recurs after treatment with radiation. Laboratory studies have shown that bortezomib (Velcade), a new type of cancer drug called a proteasome inhibitor, inhibits growth of head and neck cancer cells. This clinical study is the first test of whether bortezomib can increase the effectiveness of repeat radiation treatment for patients whose head and neck cancer has recurred.
Pioglitazone for Oral Premalignant Lesions
(Posted: 04/20/2010) - In this trial, patients with oral leukoplakia will be randomly assigned to receive either pioglitazone or placebo pills daily for 6 months.
Preventing Mucositis in Head and Neck Cancer Patients
(Posted: 03/20/2007, Updated: 06/17/2008) - In this trial, patients undergoing combination chemotherapy and radiation therapy (chemoradiotherapy) for advanced head and neck cancer will receive intravenous palifermin or placebo before and during cancer treatment to prevent mucositis, a common but serious side effect of chemoradiotherapy for this type of cancer.
Chemoprevention Trial for Head and Neck Cancer
(Posted: 02/01/2005, Updated: 03/05/2008) - In this study, researchers are investigating the ability of pioglitazone, a drug used to treat type II diabetes, to reverse leukoplakia and prevent it from developing into head and neck cancer.
Treatment for Recurrent Head and Neck Cancer
(Posted: 01/31/2006, Updated: 01/08/2007) - In this clinical trial, researchers seek to determine if giving concurrent radiation therapy and chemotherapy to patients with inoperable, recurrent head and neck cancer who were treated initially with radiation therapy will improve survival rates for these patients.